EQRX Stock Overview
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
EQRx, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.34 |
52 Week High | US$3.96 |
52 Week Low | US$1.58 |
Beta | 0.48 |
1 Month Change | 5.41% |
3 Month Change | 4.46% |
1 Year Change | -36.24% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -76.79% |
Recent News & Updates
Recent updates
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely
Jul 25EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Feb 22We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate
Nov 08EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs
Aug 28 EQRx GAAP EPS of -$0.17 beats by $0.03
Aug 11Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation
Jul 24We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth
Apr 08EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Dec 24Shareholder Returns
EQRX | US Biotechs | US Market | |
---|---|---|---|
7D | -5.3% | -2.5% | -3.2% |
1Y | -36.2% | -3.7% | 19.3% |
Return vs Industry: EQRX underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: EQRX underperformed the US Market which returned 14.1% over the past year.
Price Volatility
EQRX volatility | |
---|---|
EQRX Average Weekly Movement | 4.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EQRX has not had significant price volatility in the past 3 months.
Volatility Over Time: EQRX's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 362 | Melanie Nallicheri | www.eqrx.com |
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company’s clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis.
EQRx, Inc. Fundamentals Summary
EQRX fundamental statistics | |
---|---|
Market cap | US$1.14b |
Earnings (TTM) | -US$260.31m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs EQRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EQRX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$260.32m |
Earnings | -US$260.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.54 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did EQRX perform over the long term?
See historical performance and comparison